Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases.

ABSTRACT:

Background

Considering the considerable prevalence of allergic disease in the general population, an urgent need exists for inactivated SARS-CoV-2 vaccines that can be safely administered to those subjects.

Methods

This retrospective cohort study including 1926 participants who received inactivated SARS-CoV-2 vaccines, compared their local and systemic reactions in 7 days after each dose of inactivated SARS-CoV-2 vaccine, and anti-SARS-CoV-2 IgG after vaccination in all participants.

Results

Pain at the injection site within seven days after the first injection was the most commonly reported local reaction, occurring in 31.0% of the patients with allergic disease and 18.9% in the control group, respectively (P < 0.001). After the first dose, systemic events were more

SUBMITTER: Cao C 

PROVIDER: S-EPMC9137440 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature